South Africa is working to identify local manufacturers for lenacapavir, a twice-yearly injectable HIV prevention drug that showed near-perfect efficacy in clinical trials. Kenya has already received 21,000 doses of the medication.
New clinical trials show single doses of psilocybin and LSD produce significant, lasting reductions in OCD and generalized anxiety disorder symptoms for up to 12 weeks, marking a potential shift from daily medication regimens.
Summit Therapeutics will participate in three investor conferences in March 2026, following FDA acceptance of its BLA for ivonescimab in lung cancer with a PDUFA date of November 14, 2026.
Zydus Lifesciences received USFDA final approval for 32 mg bosentan tablets for pediatric PAH and Ammonium Lactate Cream, 12%, while launching an affordable respiratory device in India.
Approved gene-editing therapies for sickle cell disease priced at $2.2 million remain out of reach in Africa, where 80% of the world's cases occur, as Uganda launches mandatory newborn screening.
The Preeclampsia Foundation released a new educational resource to help OB-GYNs navigate predictive and diagnostic biomarker testing for hypertensive disorders of pregnancy, covering FDA-cleared tests from Thermo Fisher Scientific and Roche Diagnostics.
GLP-1 receptor agonists like semaglutide and liraglutide may improve fertility through metabolic benefits but are not recommended during pregnancy. Current guidance advises discontinuing long-acting agents at least two months before conception.
Zydus Lifesciences Limited received final FDA approval for Ammonium Lactate Cream, 12%, a generic of Lac-Hydrin Cream. The topical prescription medication treats xerosis and ichthyosis vulgaris, with annual U.S. sales of $15 million.
Takeda announced positive Phase 3 results for zasocitinib in adults with moderate-to-severe plaque psoriasis, meeting all 44 endpoints. The company is also conducting a Phase 3 trial in pediatric patients.
